CS242158B1 - Immune antivirus and antibacterium serum - Google Patents

Abstract

The invention relates to an immune antiviral and antibacterial sera useful in the art prevention and therapy of respiratory syndrome calves and young cattle. Contains specific antibodies to the Ad-1 virus, IBR virus virus PI-3, BVD virus and bacterial germs of Corynebacterium species pyogenes, Diplococcus pneumoniae, Pasteurella multocida, Pasteurella haemolytica Streptococcus albus and Streptococcus pneumoniae. It finds use in animal production and contributes to substantial reductions morbidity of calves and young cattle, as also to reduce economic losses incurred mortality.

Description

The present invention relates to an anti-viral and anti-viral anti-viral serum for prevention and young cattle based on a combination of specific antibodies of a viral and bacterial origin. ifi u. ,,. .

Concentration of animals into the Great-Keys brought new, under the conditions of small-scale, unknown health problems, of which, in cattle, mass respiratory diseases are particularly prominent. The development of these diseases is etiologically associated with or monospecific infections with obligatory pathogenic viruses such as Infectious Bovine Rhinotracheitis Virus (IBRj and Mucosal Disease Virus (BVDj), (McKercher DG: Bovine Respiratory Infections, J. Am. Vet. Med. Ass., 152, 729-737 (1968), or a set of viral and bacterial conditional pathogenic germs that cause a clinically manifest disease when the body's natural defenses are compromised by adverse environmental influences Umschau, 32, 511-536 (1977); McKercher DG: Bovine Respiratory Infections (J. Am. Vet. Med. Ass., 152, 729-733, 1968) .Virus infections are usually responsible for primary damage to the upper respiratory mucosa. , which allows bacterial germs regularly populating the airways to apply their pa a toxic effect, causing pathological changes in the organs and associated high morbidity and loss.

In such a situation, equipping calves with specific antibodies against both viruses and germs, or via the immune colostrum, seems to be the most effective measure in the fight against respiratory syndrome. j. vaccination of cows, or injection of immune sera prepared by hyperimmunization of production animals, respectively. specific immunoglobulins prepared therefrom.

The general immunization of cows against a wide range of infectious germs involved in the development of respiratory syndrome is technically difficult to implement in practice. More commonly, non-specific gamaglobulins are prepared from the blood of animals for slaughter (Woods G., Segre D., Bearthels C., Fritzgerald]., Brandly C .: The Role of Viruses in Respirators Diseases of Cattle VI. Outbreaks in Illinois, Veterinarian 5, 45-48, 1962). The content of antibodies against individual germs involved in the development of respiratory syndrome is normally low in normal gamaglobulins, costly and does not always produce the expected results (Perreu P .: Pneumopaties infectioeuses des jeunes bovine. Prophylaxia médicale, Rec. Med., Rec. 1147-1162, 1973). Therefore, convalescent sera have been used for the prevention and treatment of respiratory syndrome (Schoop G., Wachendorfer Go Die Parainfluenza-Insection der Kqlber un, d'7 / Behandlüng mit Rekonvaleszéntenseruní, Dtsch. Tierarztl. Wsplhjr., 1, 19, 41, 69, 41; Bartwießpjiaktóche Erfahrungen in der Propnylaxen und Therapie der Wichtigaten KS1ber- und Jungrindererkrankungen bei Grosser Tierkonzentrazion (Monatschft. Vet. Med., 27, 888-891, 1972), which, however, may, with a view to representing locally only antibodies, the use. Further progress in this direction has been the preparation of immune antiviral (Burroughs A., Korkbride C., Morril I., Freyand R., Suleimanov P .: Prophylaxis ot Parainfluenza-3 Infection in Diary Calves, Corn. Vet., 61, 85-95 Haralambiev H., Draganov M., Zwetkov P .: Hyperimmunserum against Myxovirus Parainfluenza 3 and Bovine Adenovirus in Prophylaxis ot Respirators Diseases in Calves, Arch. Exp. Vet.-Med., 273-276, 1972; , Karadzhov I., Ignatov G .: Ditproply Dissolve Ducks on a Half-Inactivated Vaccine (IBR, PI-3, Adenovirus 1.3) in Human Genetics, Vet Med Nauki, 13, 3-14, 1976; Linsert H., Beduhn M .: Klinlsche Aspekte Virusbedingter Erkrankungen des Atmungsaparates bei Kalbern, Monotshft f. Vet.-Med., 27, 561-564, 1972, or antibacterial sera (Serum against bovine bronchopneumonia / B /, product Biovety, np, Ivanovice na Hané, List of Veterinary Preparations Bioviet (CSSR, 1976), prepared hyperimmunized mprodukčných animals specified virus, respectively. germs. Application of such sera yielded alternate results depending on whether the representation against the substances in the formulation used corresponded to the infectious agents causing the disease in which they were used. For these reasons, the preparation of immune antiviral and antibacterial sera containing antibodies against the complex of bacterial bacterial germs which, either alone or in sum, have been implicated in the development of respiratory syndrome (MoellerD .: Whať with new with bovine respirator problems, j. Amer. Vet. Med. Ass., 154, 1197-100, 1969, Woods T., Mansfield, E., Krone J .: Active and Passive Immunity to Bovine Viral Respirators Diseases in Beef Calves After Shipment, Canad J. Comp. 37, 336-340 (1972). The application of such sera has proven good in the prevention and special therapy of mass respiratory diseases of calves and young cattle (Woods GT, Mansfield, E., Cmarik GF: Effect ot Certain Biology and Antibacterial Agents on Development ot Acute Respirators Tract Disease in Weaned Calves, J. Amer., Vet. Med Ass., 162, 974-978, 1973j.

For the production of immune sera, the cattle housed in the premises of the manufacturing plant are hyperimmunized with live virulent viruses and bacterins of selected microbial species and subsequently bleed repeatedly. Hyperimmunization of animals under laboratory conditions provides all the prerequisites for the production of high-quality immune sera, but is technically, time and financially demanding, which is reflected in the high price of the products. Production capacity is limited by the capacity of the stabling area and any increase above this capacity requires new Investments.

These drawbacks are solved according to the invention, which is based on the preparation of luminal antiviral and antibacterial sera used for the prevention and therapy of respiratory syndrome of calves and young cattle. This serum contains specific antibodies against adeno-1 virus (Ad-1J, infectious bovine rhinotracheitis virus (IBR), parainfluenza virus 3 (PI-3), mucosal disease virus (BVD) and against bacterial germs of Corynebacterium pyogenes, Diplococella pneumoniae, Pasteurella pneumoniae, Pasteurella multocida, Pasteurella haemolytica, Streptococcus albus and Streptococcus pneumoniae.

In view of the current epidemiological situation in the field of infectious respiratory diseases, the introduction of this preparation, which takes into account the latest knowledge of etiology and immunoprophylaxis, is at most up-to-date. Its application satisfies practical breeding conditions and the preparation can be used preventively and therapeutically. Said preparation will replace the use of various types of broad spectrum antibiotics and sulfonamides, resulting in a reduction in positive selection pressure for the appearance of resistant bacterial pathogens.

The invention can be widely used in animal husbandry in cattle breeding where it contributes substantially to reducing the incidence of respiratory diseases and subsequent deaths.

The essence of the preparation of immune antiviral and antibacterial sera is to immunize fattening cattle reared under normal operating conditions by injecting live avirulent virus strains and a multivalent inactivated oil vaccine containing viral and bacterial antigens using a single immunization schedule consisting of the two-time simultaneous preparation. 4 to 8 weeks and processing of the slaughter blood obtained at slaughter of the animals into an immunobiologically highly active preparation; this procedure allows the production of any amounts of immune serum without disturbing the normal operation and carrying out the production tasks of the farm in which it is carried out.

Example

Avirulent viruses PI-3, strain PI-3 (TiJ25-PTOB96-POB10 and BVD, strain OREGON-C24V-PTOB120-JSelO) are cultured on well-grown calf kidney cultures in Earl's medium with lactalbumin hydrolyzate. tissue, bacteriologically sterile and with the prescribed infectious disease content by titration on calf kidney tube cultures (at least 10 ^-5 TKID 50 / ml for PI-3 virus and at least 10 ° TKID 50 / ml for BVD) are added after addition of 10 volume percent dimethylsulfoxide at -20 ° C until use, but no longer than six months.

Virulent adeno viruses, strain Ad-1B-TOB21, IBR, strain IBR-R6 and IBR-BK5-PTOB8 grown on calf kidney cell cultures in Earl's medium with lactalbumin hydrolyzate, with prescribed infectious unit content (at least 10 ^{7 <J} TK1Dso / ml for the Ad-1 virus and at least 10 ⁷ ° TK / D 50 / ml for the IBR virus) are inactivated by the addition of 0.2% formaldehyde for 3 days at 30 ° C.

Bacterial species, Corynebacterium pyogenes, strain S-570 / V, Diplococcus pneumonise, strain S-69 / IL, Pasteurella multocida, strain S-1007, Pasteurella haemolytica, strain S-1017, Staphylococcus albus, strain S-467 / / 3 and Streptococcus pneumanise, strain S-366 I / a, grown in medium representing an amino acid solution obtained by enzymatic hydrolysis of delipidized soy flour, is inactivated by addition of 0.5% formaldehyde for 24 hours at 37 ° C, centrifuged in a Janetzky K70 centrifuge in metal containers for 30 minutes at 5,000 rpm. The resulting bacterial body sediment is resuspended at a rate of one part of a formalinized suspension of IBR virus and 1 to 2 parts of centrifuged bacterial cultures.

The suspension stored at 4-2 to 4-8 ° C can be used to prepare the vaccine for up to six months.

Preparation of multivalent inactivated adjuvant virus and bacterial vaccine: 1 part of inactivated Ad-1 virus, 7 parts of IBR virus and 2 parts of IBR virus containing bacteria are mixed. To one part of the inactivated virus and bacterial suspensions, one part of the adjuvant oils is added and the mixture is homogenized with a ULTRATURAX emulsifier twice for 5 minutes and 10 minutes at intervals of no more than 5 liters.

Immunization of fattening cattle: Healthy fattening cattle aged 2,5 to 3 years, with a live weight of 350 to 500 kg, are vaccinated at 1 m. equally mixed with live avirulent viruses PI-3 and BVD at a dose of 2 ml and simultaneously but separately with a multivalent inactivated adjuvant virus and bacterial vaccine at a dose of 5 ml. Vaccinated cattle, which will be picked for slaughter in 6 to 12 weeks. In revaccination, who is h242153 done in 4 to 8 weeks, i. j. Two to five weeks before landing for slaughter, 5 ml of a mixture of PI-3 virus and BVD i are administered to each animal. however, separately but separately for 10 ml of multivalent softening / oiled viral and bacterial vaccines. Blood collection and processing: Immunized cattle taken to the slaughterhouse are rescinded after 24 hours of rest. Animals must be allowed to receive healthy water ad lihidum.

At the time of slaughter, the collected blood is defibrinated, free of blood elements and the rest of the fibrin by passing through sterile gauze, poured into a cross-linked or enamelled sealed container by placing it in tanks of flowing water or in a cooler. The fresh blood is processed to the 'serum' at most 24 hours.

The series 'is satisfactory,' if free from bacterial and fungal contamination and inactivates by 10 ² TKIDo infectious units of individual viruses at least 1: 512 for the virus virus, at least 1: 32 for the IBR virus and for PI-3 and BVD at least up to a 1: 128 dilution.

Claims (2)

Immune antiviral and antibacterial serum for prevention and therapy of respiratory syndrome of calves and young cattle is characterized by containing specific antibodies against adeno · 1 virus at least 1: 512, against infectious bovine rhinotracheitis virus at least 1: 32, against parainfluenza virus 3 at least 1: : 128, mucosal virus virus at least at a titre of 1: 128 and specific antibodies against bacterial germs of Corynebacterium pyogenes, Diplococcus pneumoniae, Pasteurella multocida, Pasteurella haemolytica, Streptococcus albus and Streptococcus pneumoniae. Severography, n. p., plant 7, Most Price 2,40 Kčs